The Future of RAAS Inhibition and Dual Therapy
Looking toward the future of heart care, researchers are investigating how to make ACE inhibition even more effective. One area of focus is "dual-pathway" inhibition. Scientists have discovered that even when the primary enzyme is blocked, the body sometimes finds "escape routes" to continue producing harmful hormones through different enzymes like Chymase.
Newer therapies are being designed to block these escape routes or to combine ACE inhibitors with other types of drugs, such as Neprilysin inhibitors. This combination approach aims to not only stop the "bad" hormones from causing damage but also to boost the "good" hormones that help the heart relax and the kidneys flush out extra fluid. These advancements represent the next generation of heart failure management, building on the fifty-year legacy of the original discovery of the ACE inhibitor class.